The latest advancements in bispecific antibodies and antibody-drug conjugates continue to improve the personalized treatment of advanced non-small cell lung cancer.
ONCOLOGY Vol 39, Issue 10
Explore the latest advancements in antibody-drug conjugates for treating metastatic triple-negative breast cancer and their unique safety profiles.
Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.
AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer
2
Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC
3
Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma
4
Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC
5
